Literature DB >> 9436466

Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes.

D Reinhold1, U Bank, F Bühling, M Täger, I Born, J Faust, K Neubert, S Ansorge.   

Abstract

Various studies have shown that the ectoenzyme dipeptidyl peptidase IV (DP IV, CD26), expressed on T, NK and B cells in the human immune system, is involved in the regulation of DNA synthesis and cytokine production. The DP IV/CD26 was found also on mouse splenocytes and thymocytes. Here, we show that the specific DP IV inhibitors Lys[Z(NO2)]-thiazolidide, Lys[Z(NO2)]-pyrrolidide inhibit DNA synthesis as well as production of IL-2, IL-6 and IL-10 of PHA-stimulated mouse splenocytes and Con A-stimulated mouse thymocytes. Most importantly, these inhibitors induce a three to fourfold increased secretion of latent transforming growth factor beta 1 (TGF-beta 1) by mitogen-stimulated mouse immune cells, as measured with a specific TGF-beta 1 enzyme-linked immunosorbent assay (ELISA). These data demonstrate that CD26 plays a role also in regulation of DNA synthesis and cytokine production by murine immune cells, that the enzymatic activity is required for mediating these effects, and that TGF-beta 1 might have key functions in these processes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9436466     DOI: 10.1016/s0165-2478(97)02716-8

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  12 in total

Review 1.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

Review 2.  Targeting regulatory T cells in the treatment of type 1 diabetes mellitus.

Authors:  S M Cabrera; M R Rigby; R G Mirmira
Journal:  Curr Mol Med       Date:  2012-12       Impact factor: 2.222

Review 3.  Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitus.

Authors:  C Evans-Molina; M Hatanaka; R G Mirmira
Journal:  Diabetes Obes Metab       Date:  2013-09       Impact factor: 6.577

4.  DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes.

Authors:  Mariana Rodrigues Davanso; Carolina Caliari-Oliveira; Carlos Eduardo Barra Couri; Dimas Tadeu Covas; Angela Merice de Oliveira Leal; Júlio César Voltarelli; Kelen Cristina Ribeiro Malmegrim; Juliana Navarro Ueda Yaochite
Journal:  Inflammation       Date:  2019-04       Impact factor: 4.092

5.  Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.

Authors:  S M Cabrera; S C Colvin; S A Tersey; B Maier; J L Nadler; R G Mirmira
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

Review 6.  Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.

Authors:  Jixin Zhong; Quan Gong; Aditya Goud; Srividya Srinivasamaharaj; Sanjay Rajagopalan
Journal:  J Diabetes Res       Date:  2015-05-14       Impact factor: 4.011

Review 7.  Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.

Authors:  Quan Gong; Sanjay Rajagopalan; Jixin Zhong
Journal:  Int J Cardiol       Date:  2015-06-27       Impact factor: 4.164

8.  Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.

Authors:  Kalpit A Vora; Gene Porter; Roche Peng; Yan Cui; Kellyann Pryor; George Eiermann; Dennis M Zaller
Journal:  BMC Immunol       Date:  2009-04-09       Impact factor: 3.615

9.  Urine proteomes of healthy aging humans reveal extracellular matrix (ECM) alterations and immune system dysfunction.

Authors:  M Bakun; G Senatorski; T Rubel; A Lukasik; P Zielenkiewicz; M Dadlez; L Paczek
Journal:  Age (Dordr)       Date:  2013-08-06

Review 10.  CD26 and Asthma: a Comprehensive Review.

Authors:  Juan J Nieto-Fontarigo; Francisco J González-Barcala; Esther San José; Pilar Arias; Montserrat Nogueira; Francisco J Salgado
Journal:  Clin Rev Allergy Immunol       Date:  2019-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.